Green Owner – MZEI has limited resources to pursue the healthcare use of AS, much less other applications. In mid-2015 Ed was reportedly telling people he was trying to get to invest in debt that MZEI wouldn’t exist in its current form a year from then (i.e. it would be sold). Without getting into a discussion about the accuracy of his prediction, the comment informs one about the extent of business applications MZEI might pursue. While we may hear otherwise next week, I expect that we’ll hear that the medical use of AS is the focus.
The uses you posit have been discussed for years. What I’d like to hear about next week is any strategy to extract value from the non-medical patents and regulatory approvals. Is there a plan, as an example, to try to sell the non-medical patents/applications to a firm like Rollins, Inc. and perhaps the anthrax patent to a DOD contractor? As near as we know, there has been very little done to try to assess these other various markets. In that context, does one hope for a sufficiently large bid from a medical suitor that the alternative uses become throwaways to valuation, but potential sources of price recovery for the suitor having the capacity to develop or spin-off to those markets?
Gaining insight into deriving and extracting shareholder value could be gleaned from a working relationship with a decent investment bank. Will we hear about any such relationship next week? It will be interesting to learn just how much of this has been evaluated and plans developed in anticipation of EPA approval versus how much is yet to be done. MZEI’s history suggests sequence, but I’d like to be surprised.
